Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of May 2019, with a specific focus on a capital raise event announced on May 20, 2019, and expected to close on May 22, 2019.
Key Financial Metrics
The filing details a registered direct offering rather than operational financial results for a specific period.
- Gross Proceeds: $6,000,000 from the issuance of 1,500,000 American Depositary Shares (ADSs).
- Offering Price: $4.00 per ADS.
- Warrants Issued: Unregistered warrants to purchase 1,500,000 ADSs at an exercise price of $4.00 per ADS, expiring five and one-half years from issuance.
- Transaction Costs: A 6% cash placement fee, a $50,000 non-accountable expense allowance, and $10,000 in clearing expenses payable to H.C. Wainwright & Co., LLC.
- Placement Agent Compensation: Warrants equal to 5% of the aggregate ADSs sold (75,000 warrants) at $4.00 per ADS.
The filing text does not provide clear values for revenue, profit, operating cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the dilution of existing shareholders through the issuance of new ADSs and warrants. The company has agreed to a 30-day lock-up period following the closing, during which it cannot issue or announce the issuance of any ADSs, ordinary shares, or equivalents, subject to customary exceptions. Additionally, the company is restricted from entering into "variable rate transactions" for 13 months following the closing.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The company intends to use the proceeds to fund its operations and clinical development programs, though specific allocation details are not provided in this summary text. Management committed to filing a registration statement with the SEC by June 19, 2019, to register the resale of shares underlying the warrants.
Risks and Contingencies: The closing of the offering is subject to customary conditions. The filing includes a standard warning that forward-looking statements regarding the closing date and future performance are not guaranteed. The warrants and underlying ADSs are sold pursuant to exemptions from registration and may not be resold in the United States without an effective registration statement or applicable exemption.
Investor Verification Checklist
- Confirm the actual closing date of the offering and whether all customary conditions were satisfied.
- Verify the net proceeds received after deducting the 6% placement fee and other transaction costs.
- Review the full Securities Purchase Agreement (Exhibit 10.1) for specific covenants and representations.
- Monitor the filing of the registration statement for the warrant shares by the June 19, 2019 deadline.
- Assess the impact of the 1,500,000 new ADSs and 1,500,000 warrant shares on total outstanding share count and dilution.